Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Lowers Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has maintained an Overweight rating on Supernus Pharmaceuticals (NASDAQ:SUPN) but lowered the price target from $43 to $42.
October 25, 2023 | 7:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Supernus Pharmaceuticals' price target has been lowered from $43 to $42 by Piper Sandler, though the Overweight rating is maintained.
The news is directly about Supernus Pharmaceuticals and its rating by Piper Sandler. The lowering of the price target might indicate a slightly less optimistic outlook, but the maintenance of the Overweight rating suggests that the analyst still sees the stock as a good investment. This could have a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100